Обоснованность использования сартанов у больных артериальной гипертонией
Аннотация
Об авторе
Р. И. СтрюкРоссия
Список литературы
1. Диагностика и лечение артериальной гипертензии. Кардиоваск. тер. и проф. 2008; 7 (6; Прил. 2).
2. ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.
3. Healey J, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A meta-analysis. J Am Coll Card 2005; 45: 1832-8.
4. 4. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-6.
5. Elliott WJ, Meyer PM. Incident diabetes clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-7.
6. Neutel JM et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.
7. Lithell H, Hansson L, Skoog I et al., for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Hypertension 2003; 21: 875-6.
8. Schrader J, Luders S, Kulschewski A, MOSES Study Group et al. Morbidity and Mortality After Stroke. Eprosartan Compared with Nitrendipine for Secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-26.
9. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
10. Stumpe KO et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31-7.
11. Kunz R et al. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008; 148: 30-48.
12. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARMOverall programme. Lancet 2003; 362: 759-66.
Рецензия
Для цитирования:
Стрюк Р.И. Обоснованность использования сартанов у больных артериальной гипертонией. Системные гипертензии. 2009;(4):29-33.
For citation:
. Rationale for the use of sartans in patients with arterial hypertension. Systemic Hypertension. 2009;(4):29-33.
Послать статью по эл. почте 